Stay updated on Setmelanotide in BBS and AS for Obesity Clinical Trial

Sign up to get notified when there's something new on the Setmelanotide in BBS and AS for Obesity Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Setmelanotide in BBS and AS for Obesity Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:52:12.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update in the proportion of participants who lose ≥ 10% of their baseline body weight following treatment with setmelanotide in a study on obesity and hyperphagia in individuals with Bardet Biedl syndrome (BBS) or Alström syndrome (AS).
    Difference
    0.1%
    Check dated 2024-06-06T14:48:47.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to include detailed eligibility criteria for study participants, specifying conditions such as age, obesity status, and health requirements. Previously, it only mentioned that no information was provided about collaborators.
    Difference
    40%
    Check dated 2024-05-22T21:33:27.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:56:08.000Z thumbnail image

Stay in the know with updates to Setmelanotide in BBS and AS for Obesity Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Setmelanotide in BBS and AS for Obesity Clinical Trial page.